Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSP70-MAGE-3
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
HSP70-MAGE-3 is a recombinant fusion protein vaccine designed to enhance cellular and humoral immune responses against MAGE-3 expressing tumors. It consists of amino acids 195-314 of the melanoma antigen (MAGE) gene family member MAGE-3 covalently linked to the C-terminus of *Mycobacterium tuberculosis* Heat Shock Protein 70 (HSP70). The HSP70 component acts as a vehicle to potentiate the immune response to the MAGE-3 antigen, leading to potent antitumor immunity.
- Other names
- HSP70-MAGE-3HSP-70-MAGE-3HSP 70-MAGE-3
02
Targets
MAGEA3 (Melanoma-associated antigen 3)Hsp70 (70 kDa heat shock protein)
Beyond the preview
Go deeper on HSP70-MAGE-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSP70-MAGE-3.